Form 4: Blueprint Medicines Director Habib Dable Boosts Stake with RSU Grant

Blueprint Medicines Corporation Director Habib J Dable acquired 3,902 shares of common stock through a restricted stock unit grant on June 18, 2025, increasing his beneficial ownership to 12,644 shares.

Summary

• Habib J Dable, a Director of Blueprint Medicines Corp. (BPMC), acquired 3,902 shares of common stock.
• The transaction occurred on June 18, 2025, at an acquisition price of $128.12 per share.
• Following this transaction, Mr. Dable beneficially owns a total of 12,644 shares of Blueprint Medicines common stock.
• The acquisition was a grant of restricted stock units (RSUs), not an open market purchase.
• These restricted stock units are scheduled to vest 100% on the earlier of June 18, 2026, or the date of the Issuer's next annual meeting of stockholders.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director through an RSU grant is generally viewed positively as it aligns the director's interests with long-term shareholder value and indicates continued commitment to the company, without implying any immediate negative financial implications.

Positives

• A Director of Blueprint Medicines Corporation, Habib J Dable, increased his equity stake by acquiring 3,902 shares of common stock.
• The acquisition, through a grant of restricted stock units, aligns the director's long-term interests with those of the company's shareholders.

Risks

• The ultimate value of the restricted stock units to the reporting person is contingent upon the future market price of Blueprint Medicines Corporation's common stock until the vesting date.

Future Outlook

The restricted stock units granted to Director Habib J Dable are scheduled to vest 100% on the earlier of June 18, 2026, or the next annual meeting of the Issuer's stockholders, indicating a future equity event that will convert the RSUs into common stock.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, a common practice in the biotechnology and pharmaceutical industries. Such grants are designed to align the interests of company leadership with long-term shareholder value and are a standard component of executive and director compensation packages.

Related Party Transactions

• The reported transaction involves the grant of restricted stock units to Habib J Dable, a Director of Blueprint Medicines Corporation, which constitutes a related party transaction in the form of equity compensation.

Stakeholder Impact

• Shareholders: The transaction aligns the interests of Director Habib J Dable with shareholders by increasing his equity stake in the company, potentially fostering a greater focus on long-term performance.

Next Steps

• Vesting of 3,902 restricted stock units on the earlier of June 18, 2026, or the next annual meeting of Blueprint Medicines Corporation's stockholders.

Key Dates

Keywords

Blueprint Medicines, BPMC, Form 4, Insider Transaction, Director, Restricted Stock Units, RSU Grant, Equity Compensation, Stock Ownership